IE921990A1 - Medicaments - Google Patents

Medicaments

Info

Publication number: IE921990A1
Authority: IE; Ireland
Prior art keywords: tetrahydro; benzazepine; compound; hydroxy; methoxy
Prior art date: 1991-06-21

Application number

IE199092A

Other languages

English (en)

Inventor

John Gerard Ward

Rodney Christopher Young

Alberto Julio Kaumann

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-21

Filing date

1992-07-01

Publication date

1992-12-30

1991-06-21 Priority claimed from GB919113377A external-priority patent/GB9113377D0/en

1991-06-21 Priority claimed from GB919113379A external-priority patent/GB9113379D0/en

1992-07-01 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1992-12-30 Publication of IE921990A1 publication Critical patent/IE921990A1/en

Links

239000003814 drug Substances 0.000 title claims abstract description 12
150000001875 compounds Chemical class 0.000 claims description 70
238000011282 treatment Methods 0.000 claims description 29
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 20
238000000034 method Methods 0.000 claims description 17
208000019695 Migraine disease Diseases 0.000 claims description 16
239000000556 agonist Substances 0.000 claims description 16
229910052739 hydrogen Inorganic materials 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 16
206010027599 migraine Diseases 0.000 claims description 16
208000007232 portal hypertension Diseases 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
150000002431 hydrogen Chemical class 0.000 claims description 9
239000000018 receptor agonist Substances 0.000 claims description 9
229940044601 receptor agonist Drugs 0.000 claims description 9
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 claims description 8
108091005479 5-HT2 receptors Proteins 0.000 claims description 8
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
239000007800 oxidant agent Substances 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 claims description 3
QXOPSEFXKXDFCS-UHFFFAOYSA-N 8-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound C1CCCNC2=C1C=C(OC)C(Br)=C2 QXOPSEFXKXDFCS-UHFFFAOYSA-N 0.000 claims description 2
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims description 2
230000002140 halogenating effect Effects 0.000 claims description 2
230000000802 nitrating effect Effects 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 2
AHXWNPZRTBMBJW-UHFFFAOYSA-N 1-(7-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)ethanone Chemical compound N1CCCCC2=C1C=C(C(=O)C)C(O)=C2 AHXWNPZRTBMBJW-UHFFFAOYSA-N 0.000 claims 1
KLRQDJSMGYOZMZ-UHFFFAOYSA-N 7-bromo-2,3,4,5-tetrahydro-1h-1-benzazepin-8-ol Chemical compound N1CCCCC2=C1C=C(O)C(Br)=C2 KLRQDJSMGYOZMZ-UHFFFAOYSA-N 0.000 claims 1
NYHWCJTZGDKRIJ-UHFFFAOYSA-N 7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=C([N+]([O-])=O)C(OC)=CC=C21 NYHWCJTZGDKRIJ-UHFFFAOYSA-N 0.000 claims 1
WGZBAEWYTXWWCV-UHFFFAOYSA-N 7-methoxy-8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound C1CCCNC2=C1C=C(OC)C([N+]([O-])=O)=C2 WGZBAEWYTXWWCV-UHFFFAOYSA-N 0.000 claims 1
VJNXUPYYYSVGHS-UHFFFAOYSA-N 8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound C1CCCNC2=C1C=C(O)C([N+]([O-])=O)=C2 VJNXUPYYYSVGHS-UHFFFAOYSA-N 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical class N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 abstract description 7
239000000243 solution Substances 0.000 description 42
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
239000000203 mixture Substances 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
239000000047 product Substances 0.000 description 16
239000007787 solid Substances 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
238000012360 testing method Methods 0.000 description 13
230000000694 effects Effects 0.000 description 11
238000003756 stirring Methods 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
-1 methylsulphonyl Chemical group 0.000 description 9
238000010992 reflux Methods 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000000284 extract Substances 0.000 description 8
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
229910052681 coesite Inorganic materials 0.000 description 6
229910052906 cristobalite Inorganic materials 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
229910052682 stishovite Inorganic materials 0.000 description 6
239000000725 suspension Substances 0.000 description 6
229910052905 tridymite Inorganic materials 0.000 description 6
AFCXBOVGVJGZSY-UHFFFAOYSA-N 8-methylsulfonyl-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound N1CCCCC2=C1C=C(S(=O)(=O)C)C(O)=C2 AFCXBOVGVJGZSY-UHFFFAOYSA-N 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
239000004031 partial agonist Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
239000013078 crystal Substances 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
GZBOOGQTVWTMSO-UHFFFAOYSA-N 7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=C([N+]([O-])=O)C(OC)=CC=C21 GZBOOGQTVWTMSO-UHFFFAOYSA-N 0.000 description 3
TVHCFCUDQLGIEU-UHFFFAOYSA-N 7-methoxy-8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(OC)C([N+]([O-])=O)=C2 TVHCFCUDQLGIEU-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940072107 ascorbate Drugs 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
210000001841 basilar artery Anatomy 0.000 description 3
229960003920 cocaine Drugs 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
229960005417 ketanserin Drugs 0.000 description 3
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
229960001289 prazosin Drugs 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
239000002904 solvent Substances 0.000 description 3
YUMSLMZQFJSQFJ-UHFFFAOYSA-N 1-(6-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(C)=O)CCC2=C(Br)C(OC)=CC=C21 YUMSLMZQFJSQFJ-UHFFFAOYSA-N 0.000 description 2
ZMUOBKSIFIWSOH-UHFFFAOYSA-N 1-(7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone;hydrochloride Chemical compound Cl.N1CC(C(C)=O)CCC2=CC(OC)=CC=C21 ZMUOBKSIFIWSOH-UHFFFAOYSA-N 0.000 description 2
SRFHAOKZRXCDNB-UHFFFAOYSA-N 1-(8-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(Br)=C2 SRFHAOKZRXCDNB-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
XXJBFTZRNFDGDV-UHFFFAOYSA-N 6-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=C(Br)C(OC)=CC=C21 XXJBFTZRNFDGDV-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000017228 Gastrointestinal motility disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
210000002565 arteriole Anatomy 0.000 description 2
239000012267 brine Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 2
229960004943 ergotamine Drugs 0.000 description 2
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000005658 halogenation reaction Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
238000006396 nitration reaction Methods 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
210000003752 saphenous vein Anatomy 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
BQZZRUBMHMBJPH-UHFFFAOYSA-N 1-(7-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)ethanone;hydrochloride Chemical compound Cl.N1CCCCC2=C1C=C(C(=O)C)C(O)=C2 BQZZRUBMHMBJPH-UHFFFAOYSA-N 0.000 description 1
MXQZWBASVYAGPH-UHFFFAOYSA-N 1-(7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(C)=O)CCC2=CC(OC)=CC=C21 MXQZWBASVYAGPH-UHFFFAOYSA-N 0.000 description 1
GLXVADCXADCGTO-UHFFFAOYSA-N 1-(7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(C)=O)CCC2=C([N+]([O-])=O)C(OC)=CC=C21 GLXVADCXADCGTO-UHFFFAOYSA-N 0.000 description 1
RFVBRODPPJECBI-UHFFFAOYSA-N 1-(7-methoxy-8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C([N+]([O-])=O)=C2 RFVBRODPPJECBI-UHFFFAOYSA-N 0.000 description 1
QRAOLIUHDOZBGF-UHFFFAOYSA-N 1-(7-methoxy-8-sulfanyl-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(S)=C2 QRAOLIUHDOZBGF-UHFFFAOYSA-N 0.000 description 1
ZVBGDZMBUHKIHG-UHFFFAOYSA-N 1-[7-methoxy-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl]ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(C(F)(F)F)=C2 ZVBGDZMBUHKIHG-UHFFFAOYSA-N 0.000 description 1
KADWRBHSBGKRMK-UHFFFAOYSA-N 1-[7-methoxy-8-(trifluoromethylsulfonyl)-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl]ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(S(=O)(=O)C(F)(F)F)=C2 KADWRBHSBGKRMK-UHFFFAOYSA-N 0.000 description 1
MGRUKQRWLMXJDP-UHFFFAOYSA-N 1-methylsulfonyl-2,3,4,5-tetrahydro-1-benzazepine Chemical compound CS(=O)(=O)N1CCCCC2=CC=CC=C12 MGRUKQRWLMXJDP-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AESTUMJPPFCEJQ-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=CC=CC=C21 AESTUMJPPFCEJQ-UHFFFAOYSA-N 0.000 description 1
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
TZDYNMUCJXCUGW-UHFFFAOYSA-N 3-acetyl-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine-8-sulfonyl chloride Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(S(Cl)(=O)=O)=C2 TZDYNMUCJXCUGW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
HOBVGWUEGWDWTB-UHFFFAOYSA-N 7-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepine-8-sulfonamide Chemical compound N1CCCCC2=C1C=C(S(=O)(=O)N)C(O)=C2 HOBVGWUEGWDWTB-UHFFFAOYSA-N 0.000 description 1
NHVNVQPRDOOVGK-UHFFFAOYSA-N 8-bromo-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound C1CCCNC2=C1C=C(O)C(Br)=C2 NHVNVQPRDOOVGK-UHFFFAOYSA-N 0.000 description 1
WCNOYYPORKEYDQ-UHFFFAOYSA-N 8-bromo-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(O)C(Br)=C2 WCNOYYPORKEYDQ-UHFFFAOYSA-N 0.000 description 1
TVYXETGKJAEWIC-UHFFFAOYSA-N 8-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(OC)C(Br)=C2 TVYXETGKJAEWIC-UHFFFAOYSA-N 0.000 description 1
WCYXJUWAKAVQPX-UHFFFAOYSA-N 8-methylsulfinyl-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound N1CCCCC2=C1C=C(S(=O)C)C(O)=C2 WCYXJUWAKAVQPX-UHFFFAOYSA-N 0.000 description 1
XBLPBGVEJSJYHB-UHFFFAOYSA-N 8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(O)C([N+]([O-])=O)=C2 XBLPBGVEJSJYHB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010013753 Drug withdrawal headache Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229910001111 Fine metal Inorganic materials 0.000 description 1
101100295738 Gallus gallus COR3 gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
229930195714 L-glutamate Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
206010034960 Photophobia Diseases 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
206010056091 Varices oesophageal Diseases 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000011340 continuous therapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
LUZRJRNZXALNLM-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 LUZRJRNZXALNLM-JGRZULCMSA-N 0.000 description 1
229960004704 dihydroergotamine Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
208000024170 esophageal varices Diseases 0.000 description 1
201000010120 esophageal varix Diseases 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
229960000582 mepyramine Drugs 0.000 description 1
210000001363 mesenteric artery superior Anatomy 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
229960001186 methysergide Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100001160 nonlethal Toxicity 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
239000011505 plaster Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008325 portal venous blood flow Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
210000001994 temporal artery Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
VPAYJEUHKVESSD-UHFFFAOYSA-N trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Hydrogenated Pyridines (AREA)

IE199092A 1991-06-21 1992-07-01 Medicaments IE921990A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919113377A GB9113377D0 (en)	1991-06-21	1991-06-21	Medicaments
GB919113379A GB9113379D0 (en)	1991-06-21	1991-06-21	Medicaments

Publications (1)

Publication Number	Publication Date
IE921990A1 true IE921990A1 (en)	1992-12-30

Family

ID=26299102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE199092A IE921990A1 (en)	1991-06-21	1992-07-01	Medicaments

Country Status (9)

Country	Link
EP (1)	EP0589973A1 (ja)
JP (1)	JPH06508352A (ja)
KR (1)	KR940701258A (ja)
AU (1)	AU1927992A (ja)
CA (1)	CA2110575A1 (ja)
IE (1)	IE921990A1 (ja)
MX (1)	MX9203012A (ja)
PT (1)	PT100602A (ja)
WO (1)	WO1993000094A2 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9211277D0 (en)	1992-05-28	1992-07-15	Glaxo Group Inc	Pharmaceutical compositions
CZ298398A3 (cs) *	1996-03-25	1999-06-16	Eli Lilly And Company	Farmaceutický přípravek
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
WO2002074746A1 (en) *	2001-03-16	2002-09-26	Yamanouchi Pharmaceutical Co., Ltd.	Benzazepine derivatives
US6953787B2 (en) *	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
KR100897642B1 (ko)	2002-12-20	2009-05-14	글락소 그룹 리미티드	신경 장애 치료용 벤즈아제핀 유도체
PL2332921T3 (pl)	2003-06-17	2016-08-31	Arena Pharm Inc	Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny
CN1805938B (zh)	2003-06-17	2010-06-16	艾尼纳制药公司	用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
TW200510324A (en) *	2003-08-11	2005-03-16	Lilly Co Eli	6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
NZ555981A (en)	2004-12-21	2011-01-28	Arena Pharm Inc	Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
BRPI0515862A2 (pt)	2004-12-23	2011-10-11	Arena Pharm Inc	uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas
EP2001852A2 (en)	2006-04-03	2008-12-17	Arena Pharmaceuticals, Inc.	Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
CN101547892B (zh)	2006-12-05	2014-08-20	艾尼纳制药公司	制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
EP2288585A1 (en)	2008-03-04	2011-03-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
US8952197B2 (en)	2009-06-18	2015-02-10	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
US9045431B2 (en)	2010-06-02	2015-06-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
AU2011296015B2 (en)	2010-09-01	2015-11-12	Arena Pharmaceuticals, Inc.	Administration of lorcaserin to individuals with renal impairment
AU2011296027A1 (en) *	2010-09-01	2013-04-04	Arena Pharmaceuticals, Inc.	Fast-dissolve dosage forms of 5-HT2C agonists
JP6272695B2 (ja)	2010-09-01	2018-01-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
JP2013536859A (ja) *	2010-09-01	2013-09-26	アリーナファーマシューティカルズ，インコーポレイテッド	５−ｈｔ２ｃアゴニストの非吸湿性塩
KR20130138770A (ko)	2010-09-01	2013-12-19	아레나 파마슈티칼스, 인크.	광학적으로 활성 산을 갖는 로르카세린의 염
JP2015534563A (ja)	2012-10-09	2015-12-03	アリーナファーマシューティカルズ，インコーポレイテッド	体重管理の方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4659706A (en) *	1985-12-20	1987-04-21	Smithkline Beckman Corporation	Sulfinyl and sulfonyl substituted 3-benzazepines

1992
- 1992-06-17 WO PCT/GB1992/001083 patent/WO1993000094A2/en not_active Ceased
- 1992-06-17 EP EP92912293A patent/EP0589973A1/en not_active Withdrawn
- 1992-06-17 KR KR1019930703940A patent/KR940701258A/ko not_active Withdrawn
- 1992-06-17 AU AU19279/92A patent/AU1927992A/en not_active Abandoned
- 1992-06-17 CA CA002110575A patent/CA2110575A1/en not_active Abandoned
- 1992-06-17 JP JP4511087A patent/JPH06508352A/ja active Pending
- 1992-06-17 PT PT100602A patent/PT100602A/pt not_active Application Discontinuation
- 1992-06-19 MX MX9203012A patent/MX9203012A/es unknown
- 1992-07-01 IE IE199092A patent/IE921990A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX9203012A (es)	1993-07-01
WO1993000094A3 (en)	1993-03-04
JPH06508352A (ja)	1994-09-22
AU1927992A (en)	1993-01-25
EP0589973A1 (en)	1994-04-06
WO1993000094A2 (en)	1993-01-07
CA2110575A1 (en)	1993-01-07
PT100602A (pt)	1993-09-30
KR940701258A (ko)	1994-05-28

Legal Events

Date	Code	Title	Description
2004-03-24	FC9A	Application refused sect. 31(1)

Publication	Publication Date	Title
IE921990A1 (en)	1992-12-30	Medicaments
AU2002228007B2 (en)	2007-06-21	Indole derivatives and their use as 5-HT2b and 5-HT2c receptor ligands
KR910000251B1 (ko)	1991-01-23	비시클로 치환된 페닐아세토니트릴 유도체
US4520025A (en)	1985-05-28	Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
CZ398191A3 (en)	1993-02-17	Novel 4-amino alkyl-2(3h)-indolones and pharmaceutical compositions containing them
SK3612000A3 (en)	2000-09-12	Sustained release tablet formulation to treat parkinson disease
EP1206264A2 (en)	2002-05-22	Compositions and methods for treating opiate intolerance
WO1999020620A1 (en)	1999-04-29	Isoquinoline derivative and drug
WO2000028993A1 (en)	2000-05-25	Serotonin ligands as pro-erectile compounds
KR20130112848A (ko)	2013-10-14	5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
JP2000512291A (ja)	2000-09-19	新規な化合物
HU201731B (en)	1990-12-28	Process for producing substituted benzamides and pharmaceutical compositions comprising such active ingredient
JPH06506442A (ja)	1994-07-21	１−（４−アシルアミノフェニル）−７，８−メチレンジオキシ−５ｈ−２，３−ベンゾ−ジアゼピン誘導体及びその酸付加塩、それを含む製薬学的組成物及びその製造方法
EP0238281A1 (en)	1987-09-23	Selective alpha-adrenergic receptor antagonists
JPH08283247A (ja)	1996-10-29	１−［２−（置換ビニル）］−３，４−ジヒドロ−５ｈ−２，３−ベンゾジアゼピン誘導体
EP1059090A1 (en)	2000-12-13	Remedies for brain infarction
JPWO2005079845A1 (ja)	2007-08-02	片頭痛予防薬
JPS62265270A (ja)	1987-11-18	新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CZ321095A3 (en)	1996-09-11	Heterocyclic compounds
EP0382618B1 (fr)	1995-09-20	Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
US4414224A (en)	1983-11-08	Pharmaceutical composition and methods for producing dopamine agonist activity
EP0382628B1 (fr)	1994-05-04	Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
JP4216337B2 (ja)	2009-01-28	ベンゾ［ｇ］キノリン誘導体
EA003991B1 (ru)	2003-12-25	Производные 2-аминопиридинов, способ ингибирования синтазы оксида азота, фармацевтические композиции и способы лечения
KR20020012314A (ko)	2002-02-15	빈뇨 혹은 요실금의 치료 또는 예방제